Staar Surgical Co. (NASDAQ:STAA)’s share price rose 2.1% on Thursday . The company traded as high as $9.00 and last traded at $8.95, with a volume of 70,416 shares traded. The stock had previously closed at $8.77.

STAA has been the subject of a number of research reports. Benchmark Co. upgraded shares of Staar Surgical from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Wednesday, May 18th. Stephens lowered shares of Staar Surgical from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 12th. Zacks Investment Research upgraded shares of Staar Surgical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 13th. William Blair restated a “market perform” rating on shares of Staar Surgical in a research report on Thursday, August 4th. Finally, Canaccord Genuity restated a “hold” rating and set a $7.00 target price on shares of Staar Surgical in a research report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Staar Surgical currently has an average rating of “Hold” and an average target price of $7.50.

The stock’s 50 day moving average price is $7.58 and its 200-day moving average price is $6.82. The firm’s market cap is $359.84 million.

Staar Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). The company earned $21 million during the quarter, compared to analyst estimates of $19.88 million. Staar Surgical’s quarterly revenue was up 12.4% on a year-over-year basis. On average, analysts forecast that Staar Surgical Co. will post ($0.31) EPS for the current year.

In related news, major shareholder Broadwood Partners Lp purchased 14,144 shares of the company’s stock in a transaction that occurred on Wednesday, June 29th. The shares were purchased at an average price of $5.24 per share, with a total value of $74,114.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.